

Summary of financial information of Concord Biotech Japan K.K. (Joint Venture of Concord Biotech Limited) for the year ended 31 March 2023, 31 March 2022 and 31 March 2021

(Amounts in JPY Millions except no. of shares and per share data)

Particulars		2022-23	2021-22	2020-21
		JPY	JPY	JPY
Sales	A	1059.80	650.80	504.15
Profit after tax	B	56.11	24.46	27.64
Equity	C	20.00	20.00	20.00
Reserves (Accumulated Earnings)	D	119.59	63.48	39.02
Weighted average no. of Shares	E	400.00	400.00	400.00
Earnings per share	(B / E)	1,40,276.02	61,150.32	69,103.01
Diluted earnings per share	(B / E)	1,40,276.02	61,150.32	69,103.01
Net asset value per share	{(C+D) / E}	3,48,985.23	2,08,709.21	1,47,558.89